BRD4-mediated repression of p53 is a target for combination therapy in AML
A.-L. Latif, A. Newcombe, S. Li, K. Gilroy, N. Robertson, X. Lei, H. Stewart, J. Cole, M. T. Terradas, L. Rishi, L. McGarry, C. McKeeve, C. Reid, W. Clark, J. Campos, , P. D. Adams
This study shows that combining MDM2 inhibitors and BET inhibitors synergistically kills AML cells by enhancing p53 activation through BRD4's repressive function.
bioRxiv · Sep 16, 2020Cell Biology